Wedbush Reiterates Outperform on Climb Bio, Maintains $20 Price Target

Benzinga Newsdesk www.benzinga.com Negative 73.0%

Neg 73% Neu 0% Pos 0%

Wedbush analyst Laura Chico reiterates Climb Bio (NASDAQ:CLYM) with a Outperform and maintains $20 price target.

Comments

No comments yet. Be the first!